|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.33 USD | +2.27% |
|
+0.28% | +18.88% |
| 08-06 | Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating | MT |
| 08-05 | Arcus Biosciences, Inc., Q2 2026 Earnings Call, Aug 05, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ARCUS BIOSCIENCES, INC. | Other Biotechnology & Medical Research | +2.27% | +0.28% | +18.88% | +198.52% | +3.93% | 3.56B |  |  | |
- Stock Market
- Stocks
- RCUS Stock
- Charts Arcus Biosciences, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
